Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Biotech Researchers Invited to Use an Automated, High-Capacity Target Capture-Sequencing Service

By BiotechDaily International staff writers
Posted on 13 Jan 2012
Researchers in need of DNA sequencing data can avail themselves of a new service that provides completely automated, high capacity, target capture-sequencing data, and streamlines sample preparation for targeted next-generation sequencing.

The new service, called targeted resequencing, is an innovation of Beckman Coulter Genomics (Danvers, MA, USA), a leading provider of genomic services and nucleic acid purification products.

Functionally, the service relies on the combination of “Agilent SureSelect Target Enrichment” technology with Beckman Coulter’s “SPRIworks Fragment Library System” for automated library construction and “Biomek Laboratory Automation Workstation” for liquid handling. This platform provides high quality, reproducible samples ready for sequencing. Beckman Coulter Genomics automated target capture solution allows for whole exome capture or custom targeting of genomic regions of interest. Sequencing on the Illumina GAII or HiSeq 2000 instruments provides accurate data with reduced project turnaround time resulting from workflow automation and flexible sample multiplexing options.

“By automating this pipeline and maximizing our target capture sequencing capacity, we are able to offer our customers a high-throughput solution, with faster project turnaround times and reproducible sequencing data,” said Dr. William Donahue, manager of molecular biology for Beckman Coulter Genomics. “Our LIMS [laboratory information management system] sample tracking also enables large numbers of samples to be processed at the same time, significantly reducing the risk of sample mix-up that exists in a manual process.”

Results are delivered via a secure FTP site or are shipped on a portable hard drive depending upon the size of the dataset.

Related Links:

Beckman Coulter Genomics


Channels

Business

view channel

License Agreement to Promote Development of Therapeutic CDK Inhibitors

A license agreement has been signed that was designed to promote the development and commercialization of a series of highly-selective cyclin-dependent kinase 7 (CDK7) inhibitors for the treatment of cancer, inflammation, and viral infections. Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle control... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.